Business Coach
9562
Daiwa Cycle
5888
Heartseed
219A
Liberta
4935
D. Western Therapeutics Institute
4576
(Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | (Q3)Oct 31, 2023 | (Q2)Jul 31, 2023 | (Q1)Apr 30, 2023 | (FY)Jan 31, 2023 | (Q4)Jan 31, 2023 | (Q3)Oct 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 10.77%313.08M | 13.26%310.23M | 18.82%1.17B | 16.23%317.18M | 22.30%297.95M | 17.54%282.64M | 19.57%273.91M | 9.20%986.06M | 15.52%272.89M | 7.43%243.62M |
Cost of revenue | 25.57%202.32M | 19.40%197.32M | 8.12%687.76M | 22.70%191.14M | 7.02%170.24M | -0.13%161.12M | 3.33%165.26M | 0.52%636.12M | -0.17%155.78M | 3.41%159.08M |
Gross profit | -8.85%110.76M | 3.92%112.91M | 38.28%483.91M | 7.61%126.03M | 51.05%127.7M | 53.56%121.52M | 57.15%108.65M | 29.56%349.94M | 46.03%117.12M | 15.90%84.55M |
Operating expense | ||||||||||
Operating profit | -8.85%110.76M | 3.92%112.91M | 38.28%483.91M | 7.61%126.03M | 51.05%127.7M | 53.56%121.52M | 57.15%108.65M | 29.56%349.94M | 46.03%117.12M | 15.90%84.55M |
Net non-operating interest income (expenses) | 1K | 33.33%8K | 20.00%18K | 0 | 20.00%12K | 0 | 20.00%6K | 15.38%15K | 0 | 25.00%10K |
Non-operating interest income | --1K | 33.33%8K | 20.00%18K | --0 | 20.00%12K | --0 | 20.00%6K | 15.38%15K | --0 | 25.00%10K |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -387K | 0 | ||||||||
Less:Other special charges | ---- | ---- | --387K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | -451.90%-436K | 30.83%-92K | -468.48%-678K | -317.82%-220K | -246K | -203.95%-79K | -2,000.00%-133K | -72.70%184K | 494.12%101K | 0 |
Income before tax | -9.15%110.33M | 3.97%112.83M | 37.91%482.86M | 7.00%125.43M | 50.75%127.47M | 53.31%121.44M | 56.94%108.52M | 29.30%350.14M | 46.13%117.22M | 15.87%84.56M |
Income tax | -3.07%37.68M | 13.86%40.26M | 37.22%157.97M | 8.55%42.59M | 49.36%41.15M | 50.63%38.88M | 56.94%35.36M | 30.47%115.12M | 39.12%39.23M | 19.85%27.55M |
Net income | -12.01%72.65M | -0.82%72.57M | 38.24%324.89M | 6.22%82.84M | 51.42%86.32M | 54.60%82.57M | 56.94%73.17M | 28.74%235.02M | 49.93%77.99M | 14.05%57.01M |
Net income continuous operations | -12.01%72.65M | -0.82%72.57M | 38.24%324.89M | 6.22%82.84M | 51.42%86.32M | 54.60%82.57M | 56.94%73.17M | 28.74%235.02M | 49.93%77.99M | 14.05%57.01M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | -12.01%72.65M | -0.82%72.57M | 38.24%324.89M | 6.22%82.84M | 51.42%86.32M | 54.60%82.57M | 56.94%73.17M | 28.74%235.02M | 49.93%77.99M | 14.05%57.01M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -12.01%72.65M | -0.82%72.57M | 38.24%324.89M | 6.22%82.84M | 51.42%86.32M | 54.60%82.57M | 56.94%73.17M | 28.74%235.02M | 49.93%77.99M | 14.05%57.01M |
Gross dividend payment | ||||||||||
Basic earnings per share | -12.03%14.85 | -0.80%14.84 | 38.22%66.43 | 6.14%16.93 | 51.46%17.66 | 54.58%16.88 | 56.98%14.96 | 28.74%48.06 | 49.91%15.95 | 14.09%11.66 |
Diluted earnings per share | -12.03%14.85 | -0.80%14.84 | 38.22%66.43 | 6.17%16.93 | 51.42%17.651 | 54.58%16.88 | 56.98%14.96 | 28.74%48.06 | 49.93%15.9463 | 14.06%11.6567 |
Dividend per share | 0 | 0 | 38.46%18 | 38.46%18 | 0 | 0 | 0 | 30.00%13 | 30.00%13 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |